Calyxt and Cibus Merging to Create Precision Gene Editing and Trait Licensing Company

(24/7 MARKET NEWS) – Calyxt, Inc. (Nasdaq: CLXT) and Cibus announced, this morning, that they entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction, to create a new industry-leading company that combines the two pioneers in agriculture-based gene editing and establishes one of the world’s most sophisticated facilities for trait development and next-generation plant breeding.

Calyxt is trading at $0.316, up $0.13 (+69.95%), on 4.6 million shares.

Its 52-week range is $0.125 to $2.14. Its next inflection points are $0.33 and $0.55. If can break through the 55-cents resistance level, on strong volume, it could try to challenge its April and March trading levels.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist